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ABSTRACT 
OECD countries face the multiple challenges of rapidly ageing societies with the associated rise in 
chronic diseases and the ever-present threat from new or evolving communicable diseases. This is within 
the context of seeking better value for money from the health sector. While a growing body of evidence 
shows that many health promotion and disease prevention measures can improve health outcomes at 
relatively low cost, less has been documented – in an internationally comparable way – on how much 
countries actually invest in such activities and the drivers of prevention spending over the years. This is 
particularly pertinent in the context of fiscal sustainability and tight public budgets. 
Using newly available data from across OECD countries, this study examines the differences in 
spending on prevention both at an aggregate and detailed level. This analysis brings a fresh perspective and 
raises questions as to the optimal resource allocations within the sector. Time series data is also scrutinised 
in conjunction with collated policy and public health developments from a number of countries to try to 
identify some of the drivers behind the observed prevention spending trends. In doing so, directions for 
further improvement in the underlying data as well as policy implications are discussed. 
RÉSUMÉ 
Les pays de l’OCDE doivent relever de nombreux défis liés au vieillissement accéléré de la 
population, accompagné d’une montée des maladies chroniques, et à la menace permanente des maladies 
contagieuses (qui apparaissent ou qui évoluent). Or, parallèlement, le secteur de la santé vise un rapport 
qualité-prix toujours meilleur. Les preuves s’accumulent sur l’efficacité de nombreuses mesures de 
promotion de la santé et de prévention des maladies à un coût relativement bas. En revanche, il existe peu 
de données permettant une comparaison entre pays en ce qui concerne les investissements dans ces 
domaines et les déterminants de l’évolution des dépenses de prévention au fil des années. Or, cet aspect est 
particulièrement important face à la question de la viabilité des finances publiques et des contraintes 
budgétaires. 
Grâce à de nouvelles données provenant des pays de l’OCDE, nous étudions les différences en 
matière de dépenses consacrées à la prévention au niveau global et en détail. Cette analyse adopte un point 
de vue novateur et soulève des questions sur l’allocation optimale des ressources dans le secteur. Les 
données chronologiques sont également examinées en même temps que l’évolution des politiques et de la 
santé publique dans différents pays afin de déceler les facteurs derrière les tendances en matière de 
dépenses de prévention. Il est ainsi possible de discuter des orientations susceptibles de contribuer à 
améliorer la collecte des données et les retombées des politiques. 
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KEY FINDINGS 
 
Note: Data refer to the OECD average for 2015 (top panel) and 2006-2015 (bottom panel). 
Source: OECD Health Statistics 2017. 
1. Prevention is an essential component of an effective health system. Whether targeted at 
individuals or populations, interventions aim to enhance health status and maintain a state of low risk for 
diseases, disorders or conditions, that is, to prevent their occurrence through programmes of information, 
immunisation, screening or monitoring. Over recent decades, there have been a number of public health 
success stories with increasing coverage of populations in terms of immunisation and screening as well as 
achievements in reducing accidents and lowering smoking and drinking rates through specific policy 
measures. Public health challenges remain as obesity rates both among adults and children risk an 
explosion of related illnesses and conditions if left unchecked. At the same time, the threat from infectious 
diseases, both old and new, requires health systems to be alert and responsive. 
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2. While many prevention activities have been shown to be cost-effective, less has been 
documented – in an internationally comparable way – about the amount that countries actually spend on 
prevention and public health services and the trends in spending over recent years. To assist in this task, 
this study uses recently published spending figures collected from OECD countries according to the 
System of Health Accounts (SHA), a globally adopted framework for reporting and tracking health 
expenditure in a consistent and harmonised way. Supplementary research on policies and public health 
developments is used to explain the observations, while identifying areas where further strengthening of 
reporting is needed. The main findings are: 
 Only a small fraction of health spending goes on prevention activities. OECD countries 
allocate less than 3% of their health spending on average to public health and prevention 
activities. Most countries fall within a band of 2 to 4% which has remained fairly stable over the 
long-term. While a number of comparability and definitional issues remain (leading to a likely 
underestimation for some countries) this perhaps represents a surprisingly low level of 
investment, given the body of evidence pointing to the cost-effectiveness of many measures, 
particularly in immunisation and some screening programmes. The study does not attempt to 
identify an optimal level of spending on prevention or a correct prevention-to-treatment 
expenditure ratio, recognising that many effective measures have minimal spending implications 
or are outside of the prevention boundary as defined in SHA. 
 A large proportion of prevention spending is on less cost-effective measures. In analysing 
spending across the various components making up prevention, a large proportion of spending 
goes on healthy condition monitoring programmes, such as check-ups and dental examinations. 
For most OECD countries such programmes were the main prevention spending category and 
accounted for nearly half of all prevention expenditure on average. Around a quarter of spending 
on average was allocated to health promotion while both immunisation and screening 
programmes accounted for less than 10% each. This finding may raise some questions for 
policymakers regarding resource allocations given that while many immunisation and some 
screening activities have been shown to be cost-effective (and some even cost-saving), there is 
less consensus on the effectiveness of general (including dental) check-ups, and particularly on 
the recommended frequency of such check-ups. While the range of activities under the 
immunisation and early disease detection categories is more homogeneous than some of the other 
prevention categories, expenditure variations between countries are still influenced by scope and 
range of national vaccination and screening plans as well as differences in unit costs. 
 Government and compulsory insurance are the main financers of preventive care. Not 
surprisingly, government or compulsory insurance schemes cover the lion’s share of prevention 
programme costs. On average, 80% of prevention spending comes from such financing schemes 
and in many countries immunisation programmes and epidemiological surveillance are under the 
responsibility of public authorities. Other types of financing do play a role in additional spending 
on health promotion (often by charities and civic society) and more notably the obligations on 
companies (14% of prevention spending) to carry out workplace medical check-ups for new and 
existing employees. The scope (as well as the reporting) of occupational health care expenditure 
can help explain a significant proportion of overall differences. 
 Spending on prevention was particularly affected following the economic crisis. Despite the 
increasingly high priority that health policymakers place on public health and prevention and 
announcements to the effect of protecting public health budgets in the wake of the global 
financial crisis, prevention spending contracted in many OECD countries in the years following 
the economic crisis. Compared with frontline services, such as inpatient and outpatient care, the 
reduction in spending growth was particularly pronounced for both pharmaceuticals and 
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prevention, perhaps deemed to be a “softer target”. The most recent years have seen renewed 
growth of prevention spending with average growth rates closer to overall health spending. 
 The H1N1 pandemic also played a role in the slowdown. The drivers behind the overall 
reduction in prevention spending growth cannot be explained by any single factor – the trends 
across countries and components are quite specific. However, to some extent the reduction of 
prevention spending growth in 2010 can also be traced to the non-crisis related impact of the 
H1N1 swine flu pandemic. The spread of the virus led to some significant one-off expenditure on 
vaccinations which in turn resulted in a peak of prevention expenditure in many countries around 
2009, with the subsequent reduction in the ensuing years. That said, overall spending for 
vaccination programmes has tended to increase over the last decade in many countries; this can 
partly be explained by the introduction of the expensive HPV vaccination into national 
immunisation plans. 
 The rollout of population-based screening programmes has pushed up spending. Increased 
spending on early disease detection can be traced to the rollout of population-based screening 
programmes in recent decades, in particular for breast and cervical cancer screening. The 
development of “population-based” screening programmes, in which patients are actively 
identified and encouraged to participate rather than where the initiative for screening originates 
from individual health providers or patients, can lead to greater overall costs. In recent years, 
colorectal cancer screening has become more widely available across OECD countries, including 
a number of countries where the nationwide rollout of population-based screening programmes 
has been completed. 
 Further reporting and harmonisation of data on prevention spending is needed. These 
findings are based on a set of comprehensive data from the majority of OECD countries on 
prevention expenditure and its components that are available for the first time. That said, 
limitations in countries’ ability to identify and report prevention spending continue to exist and 
affect data comparability. This is an iterative process and this initial analysis should stimulate and 
help countries improve their future reporting. To that aim, additional guidance to compilers of 
national health accounts about how to classify particular preventive activities should further 
improve the comparability to inform policymakers on the level and trends in prevention spending 
across countries. 
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1. INTRODUCTION 
Chronic conditions are on the rise while the risk of infectious diseases is ever-present 
3. Prevention and public health policies are a key pillar of any modern health system. Their 
importance is likely to grow in ageing societies with an increasing number of people living with one or 
more chronic (non-communicable) diseases, such as cardiovascular disease, musculoskeletal disorders, 
cancer or diabetes, while infectious diseases, both old and new, continue to pose a threat to populations in 
OECD countries and beyond. 
4. As a result of longer life expectancies and declining fertility rates, the share of the population 
aged 65 years and over is expected to almost double from 16.6% in 2015 to 27.5% by 2050 on average 
across the OECD; the increases being even more dramatic for the share of the population aged 80 years 
and over. The burden of non-communicable diseases – already accounting for the vast majority of the 
overall disease burden in OECD countries today – is expected to grow as more and more people suffer 
from one or more chronic conditions in a context of ageing societies (Figure 1). 
Figure 1. Demographic trends (2015-50) and burden of disease (DALYs, 2016), OECD average 
 
Source: OECD Health Statistics 2017; IHME (2017). 
5. Communicable diseases account for only a relatively small share of the overall disease burden in 
OECD countries. Nevertheless, recurrent outbreaks of infectious diseases that were previously thought 
under control – for example, the H1N1 pandemic in 2009 or recent measles outbreaks in unvaccinated 
populations (ECDC, 2016a; CDC, 2016) – still present challenges in OECD countries. Ensuring high 
national immunisation coverage rates can help prevent many infectious diseases while reducing the need 
for antibiotics use can stem the spread of antimicrobial resistance (AMR) (Cecchini et al., 2015). In 
addition, measures also need to be put in place to deal with potential new challenges highlighted by the 
recent Ebola pandemic in Western Africa or the world-wide spread of the Zika virus. 
Source: OECD, 2015.
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While smoking and drinking rates have fallen on average, levels of obesity continue to grow 
6. Prevention policies have seen some success in reducing behavioural risk factors, such as 
smoking, harmful alcohol use, poor diet and physical inactivity, all contributing to a high burden of chronic 
diseases. Yet, while some of these risky behaviours have been in decline in many OECD countries in 
recent years, others have been on the rise (Figure 2). Daily smoking in adults has come down markedly in 
most OECD countries over the past decade (from 25.7% in 2000 to 18.4% in 2015), even if current rates 
continue to be a major contributor to mortality in OECD countries. Much of the fall is attributable to 
individual smoking cessation interventions as well as population-based measures aimed at reducing 
tobacco consumption, including public awareness campaigns, advertising bans, increased taxation and 
smoking bans in public spaces and restaurants (OECD, 2015a).  
7. The consumption of alcohol in adults has on average decreased slightly in the past decade (from 
9.5 litres per adult in 2000 to 9.0 litres in 2015), but while some OECD countries have seen gradual 
declines in alcohol consumption since 2000, others have experienced increases. Furthermore, hazardous 
individual drinking patterns have been on the rise, such as heavy episodic drinking in young people and 
women. Recent OECD work identified a number of policies that have proven effective in tackling harmful 
alcohol use, such as counselling of heavy drinkers, improving enforcement of drinking-and-driving laws, 
increasing taxes and prices as well as regulating the marketing of alcoholic drinks (OECD, 2015b). 
8. Less progress has been made in the fight against obesity. In fact, obesity rates have been on the 
rise over the same period. In 2015, nearly one in every five adults was obese on average in OECD 
countries, up from about one in seven in 2000. To tackle the spread of obesity, a growing number of 
countries have adopted policies including public awareness campaigns, training of health professionals, 
advertising limits or bans on unhealthy food, taxations and nutrition labelling (OECD, 2017a). 
Figure 2. Development of selected behavioural risks (2000-15), OECD average 
 
Note: The OECD average only includes countries where data is available for both periods. 
1. Refers to the share of population aged 15+ who are daily smokers. 2. Refers to the share of population aged 15+ who is obese 
(Body-Mass-Index of 30 or over). 3. Refers to the consumption of pure alcohol in litres per person aged 15+. 
Source: OECD Health Statistics 2017. 
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9. Increased vaccination rates have reduced the risk of spreading some malicious diseases such as 
diphtheria, tetanus and pertussis but the outbreaks of measles in parts of Europe and the United States in 
2015 and AMR in treating some infectious diseases (e.g. gonorrhoea) show that these diseases are still not 
eradicated. And while treatment of HIV patients has much improved over recent decades, HIV 
transmission is still a major concern in OECD countries and beyond, with newly diagnosed cases 
increasing strongly, in particular in the eastern part of the WHO European Region (ECDC/WHO, 2016). 
This clearly justifies ongoing public health interventions to better fight communicable diseases. 
Getting a better handle on how much countries invest in prevention 
10. Preventing chronic diseases and related behavioural risk factors as well as the spread of 
communicable diseases requires investments in properly designed public health and prevention policies. A 
growing body of evidence makes the case for investing in health promotion and disease prevention. 
McDaid et al. (2015a) provide an extensive review of interventions for tackling specific behavioural risk 
factors including alcohol and tobacco consumption, physical inactivity and unhealthy diets as well as poor 
mental health and harmful environmental factors and find strong evidence of the cost-effectiveness of at 
least some measures in all of the covered areas. Similarly, WHO (2014) showed a wide range of preventive 
measures to be cost-effective – providing returns on investment and/or cost-savings in both the short and 
longer term – including the promotion of healthy behaviours (e.g. tobacco and alcohol legislation, reduced 
salt intake, increased physical activity), disease prevention through vaccination and screening and 
interventions addressing social and environmental health determinants. 
11. Investing in health promotion and disease prevention measures that can improve health outcomes 
at relatively low cost is of particular relevance with concerns about the fiscal sustainability of health 
systems (OECD, 2015c). The currently available evidence can therefore play an important role in 
optimising the allocation of resources within the health budget between prevention and treatment with a 
view to getting the best value for money. In England, Owen et al. (2011) analysed around 200 public health 
interventions and concluded that the majority of these interventions is highly cost-effective. In this context 
it is important to note that even though a wide range of public health interventions have been shown to be 
cost-effective, this does not necessarily imply cost-savings. While some cost-effective interventions have 
indeed the potential to reduce health care costs while improving health, others may in fact add to them 
(WHO, 2014; Cohen et al., 2008) as effective interventions may increase the lifespan of someone who 
might then go on to develop other diseases later in life (Srivastava, 2008). In other words, even if a public 
health intervention does not lead to cost-savings, the current evidence suggests that many interventions 
lead to better health outcomes at relatively low cost compared to the status quo or alternative interventions. 
Furthermore, investing in properly designed public health and prevention policies can result in substantial 
economic consequences via on the one hand a healthier and more active workforce and on the other longer 
life leading to higher pension and welfare benefits (OECD/EU, 2016).  
12. While the evidence points to spending on prevention as good value for money, rather less is 
known on how much countries actually spend on such activities and the development in spending over 
recent years. Against this background, this paper compares levels of prevention expenditure and its 
subcomponents across the OECD as well as recent trends in order to gauge how much countries invest in 
health promotion and disease prevention. Using the latest available data based on a revised health 
accounting framework, the Section 2 compares prevention expenditure in the OECD and tries to identify 
some of the factors that explain cross-country differences in spending levels. Section 3 looks more closely 
at the development of prevention expenditure in recent years and further analyses the reasons behind the 
observed trends. The last section summarises the main findings and identifies possible avenues for further 
analysis. 
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2. LEVELS AND STRUCTURE OF PREVENTION SPENDING IN THE OECD 
A standard accounting framework allows for a more detailed analysis of prevention spending 
13. The most appropriate way of comparing how much countries invest in health promotion and 
disease prevention is to measure spending on such activities using standard definitions and concepts. The 
System of Health Accounts (SHA), which has been recently revised to make it respond better to policy 
needs (OECD/Eurostat/WHO, 2017), provides a comprehensive framework for reporting internationally 
comparable data on health expenditure and is organised around a tri-axial system of classifications: the 
different health care functions representing the types of health care services and goods consumed; the 
providers of these services and goods; and the financing schemes paying for them. The functional 
classification defines the overall boundary of health expenditure and is organised according to purpose, 
including services with the primary aim of prevention (Table 1). 
14. Since 2016, OECD countries have reported health expenditure and financing data according to 
the revised SHA framework. Nearly all OECD countries provided information on total prevention 
expenditure for the most recent reporting years, with around two-thirds also reporting some or all of the 
more detailed prevention subcategories. While efforts continue to fill data gaps and improve data 
comparability, the introduction of the revised SHA marked an important step for the analysis of countries’ 
investments in public health and prevention. 
Table 1. Classification of health care functions in SHA 
 
Note: The HC codes refer to the codes used in the functional classification of health care (ICHA-HC) as defined in SHA. Current 
health expenditure refers to the sum of HC.1-HC.7 (and HC.0). 
Source: OECD/Eurostat/WHO (2017). 
Defining prevention spending in the System of Health Accounts 
15. Prevention spending can be measured through the functional classification in the SHA 
framework, where the category “HC.6 Preventive care” is defined as “any measure that aims to avoid or 
reduce the number or the severity of injuries and diseases, their sequelae and complications” 
Current health expenditure
HC.1 Curative care
HC.2 Rehabilitative care
HC.3 Long-term care (health)
HC.4 Ancillary services (non-specified by function)
HC.5 Medical goods (non-specified by function)
HC.6 Preventive care
HC.6.1 Information, education and counselling programmes
HC.6.2 Immunisation programmes
HC.6.3 Early disease detection programmes
HC.6.4 Healthy condition monitoring programmes
HC.6.5 Epidemiological surveillance and risk and disease control programmes
HC.6.6 Preparing for disaster and emergency response programmes
HC.7 Governance and health system and financing administration
HC.0 Other health care services not elsewhere classified (n.e.c.)
Memorandum items: health care related
HCR.1 Long-term care (social)
HCR.2 Health promotion with a multi-sectoral approach
 DELSA/HEA/WD/HWP(2017)11 
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(OECD/Eurostat/WHO, 2017; p. 100) and covers expenditure on activities where the primary purpose is to 
avoid diseases and risk factors (primary prevention) or the early detection of disease (secondary 
prevention). This includes both services consumed by individuals (e.g. preventive immunisation or 
screening) as well as collective services (e.g. information campaigns or epidemiological surveillance). 
16. Expenditure on tertiary prevention (i.e. reducing the negative impact of an already established 
disease or injury) is not included; rather it is accounted for under curative and rehabilitative care in the 
SHA framework. Moreover, prevention expenditure in SHA does not include pharmaceuticals or medical 
goods with a preventive function (e.g. anti-hypertensives, statins) which are, by convention, reported under 
the medical goods category. Also not covered under spending on preventive care are costs associated with 
introducing and enforcing public health legislation. While the former are considered under the governance 
and health system administration category, the latter are outside the scope of the core accounting 
framework and can be reported as a health care related memorandum item. 
17. It is important to note that the prevention category in SHA is restricted to those activities that are 
within the health care boundary
1
, i.e. only activities with a primary health purpose are considered. In other 
words, multi-sectoral approaches of health promotion with a public health interest that go beyond health 
(e.g. environmental interventions) are not included in prevention expenditure.
2
 The definition of prevention 
employed by the SHA therefore tends to capture a narrower set of activities compared with dedicated 
public health frameworks, such as the list of Essential Public Health Operations (EPHOs) developed by the 
WHO with the “Enabler EPHOs” in particular outside the SHA prevention boundary (see Box 1). 
18. SHA also provides for a further breakdown of prevention expenditure by service type into six 
subcategories. These subcategories were re-oriented in the revision of SHA to better reflect the differences 
in the nature of the types of services facilitating a more appropriate grouping of activities 
(OECD/Eurostat/WHO, 2017; pp. 103-106): 
 Information, education and counselling programmes (HC.6.1) focus on primary and 
secondary prevention through a variety of formats, such as mass media and personal advice. 
Examples include: information about the health consequences of smoking, diet, physical activity 
or salt consumption; special warnings to pregnant women about drug abuse and alcohol 
consumption; information on risk protection effectiveness through the use of crash helmets and 
seat belts; and information on vaccination or screening programmes. 
 Immunisation programmes (HC.6.2) refer to primary prevention of a disease through the use of 
pharmaceutical products, such as vaccines. Examples include immunisation for diphtheria, 
tetanus, pertussis, measles, mumps, rubella, hepatitis, influenza and HPV. 
 Early disease detection programmes (HC.6.3) concern the active search for a specific disease 
(e.g. breast cancer, cervical cancer, HIV/AIDS) early in its course, before symptoms appear. This 
can involve screening, diagnostic tests and medical examinations. 
 Healthy condition monitoring programmes (HC.6.4) refer to the active monitoring of healthy 
conditions and are not focused on specific diseases. These can target specific conditions (e.g. 
                                                     
1. The SHA lists four main criteria to determine whether an activity is within the health care boundary and 
should therefore be included in health expenditure. These are: 1) primary purpose is health, 2) qualified 
medical and health knowledge needed, 3) consumption is for final use and 4) there is a transaction of health 
care goods and services (OECD/Eurostat/WHO, 2017; pp. 55-56). 
2. The category “Health promotion with a multi-sectoral approach” exists as a health care related 
memorandum item in SHA, but to date has not been systematically reported by OECD countries. 
DELSA/HEA/WD/HWP(2017)11 
 14 
pregnancy), specific age groups (e.g. children) or specific health domains, such as dental and 
general health check-ups. 
 Epidemiological surveillance and risk and disease control programmes (HC.6.5) includes 
conducting surveillance of outbreaks and patterns of communicable and non-communicable 
diseases and of injuries and exposure to environmental agents harmful to health, as well as 
investigating appropriate responses. Examples include: data collection on risks to human health; 
epidemiological assessment and analysis of causes and consequences of risks; and monitoring of 
drinking water in public health laboratories. 
Box 1. The 10 Essential Public Health Operations (EPHOs) and their link to SHA 
The 10 EPHOs constitute a list of essential public health functions which should be provided by any effective 
public health system. These centre around three main areas of service delivery (EPHOs 3-5) and are informed by 
public health intelligence (EPHOs 1-2) and enhanced by enablers (EPHOs 6-10): 
 
The EPHOs take a much broader view of public health and prevention than SHA. In SHA, prevention spending 
would mainly cover EPHOs 1, 2 and 5, even though not all of the activities subsumed under these EPHOs might be 
included in the SHA definition of preventive care. EPHOs 1 and 2 roughly correspond to the SHA functions HC.6.5 
(epidemiological surveillance and risk and disease control programmes) and HC.6.6 (preparing for disaster and 
emergency response programmes), respectively. EPHO 5 broadly covers SHA functions HC.6.2 (immunisation 
programmes), HC.6.3 (early disease detection programmes) and HC.6.4 (healthy condition monitoring programmes) 
with the main difference that EPHO 5 also includes tertiary prevention which is not part of prevention expenditure in 
SHA. 
While some parts of EPHOs 3 and 4 have a primary health purpose (e.g. protecting against communicable 
diseases, occupational health, maternal and child health, tackling behavioural risk factors) and would therefore be 
covered by prevention expenditure in SHA, others focus on broader social and environmental determinants (e.g. 
housing, transport, climate change) and are outside the SHA boundary. 
Enabler EPHOs are mostly not reported under prevention expenditure in SHA. Whereas some activities under 
EPHO 9 might be relevant for SHA function HC.6.1 (information, education and counselling programmes), most other 
enabler EPHOs would not be explicitly reported in SHA as they do not refer to the final consumption of health care 
services and goods. Expenditure related to (public) health governance and administration of (public) health financing, 
which are aspects of EPHOs 6 and 8, are part of SHA function HC.7 (governance and health system and financing 
administration) rather than preventive care. 
Source: WHO (2017) and authors’ assessment. 
Core EPHOs: Intelligence
1. Surveillance of population health and wellbeing
2. Monitoring and response to health hazards and emergencies
Core EPHOs: Service Delivery
3. Health protection including environmental, occupational, food safety and others
4. Health promotion including action to address social determinants and health inequality
5. Disease prevention, including early detection of illness
Enabler EPHOs
6. Assuring governance for health and wellbeing
7. Assuring a sufficient and competent public health workforce
8. Assuring sustainable organisational structures and financing
9. Advocacy communication and social mobilisation for health
10. Advancing public health research to inform policy and practice
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OECD countries spend much less on prevention compared to treatment 
19. In 2015, per capita prevention expenditure was highest in Canada and the United States with 
more than USD 250 (adjusted for differences in purchasing power) – about two-and-half times the OECD 
average (USD 116) (Figure 3). This is followed by a group of mainly northern and western European 
OECD members with above average prevention expenditure. At the other end of the spectrum is a group of 
mainly southern and central European countries with per capita prevention expenditure significantly below 
the OECD average. Prevention expenditure per capita was lowest in Greece and Latvia. Some of this 
variation can be attributed to definitional issues and data limitations (see Box 2). 
Figure 3. Prevention expenditure per capita and as a share of current health expenditure, 2015 
 
Source: OECD Health Statistics 2017. 
20. Measured as a share of current health expenditure, Figure 3 shows that in 2015 nearly all OECD 
countries allocated between 2 and 4% of all final consumption expenditure on health care services and 
goods to preventive care. Only Greece (1.3%) devoted clearly below the 2% figure to prevention, whereas 
Canada (6.2%) and the United Kingdom (5.2%) were the only countries reporting significantly more than 
4% of health expenditure to this category. On average, OECD countries dedicated 2.8% of their total health 
care bill to health promotion and disease prevention. This is much less than OECD countries’ spending on 
other health care functions (Figure 4). Across the OECD about 80% of health expenditures were devoted to 
treatment including curative and rehabilitative care services (60.3%) and medical goods (19.6%) with the 
latter consisting mainly of expenditure on pharmaceuticals (although including medicines with a 
preventive function). The remaining portion of health expenditure went to long-term care (13.7%) and 
health system administration (3.6%). 
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Figure 4. Health expenditure by function of health care, OECD average, 2015 
 
1. Includes rehabilitative and ancillary services. 
Source: OECD Health Statistics 2017. 
21. Given the importance that health policymakers in OECD countries place on public health and 
prevention in their national health strategies, it may seem surprising to see that at an aggregate level 
relatively few resources are devoted to prevention, with less money spent on prevention than on 
administration – a purely supportive health care function. Of course, many prevention activities have few 
spending implications. In spite of the general improvements in the reporting of prevention expenditure that 
have been achieved with the new SHA framework, there is reason to believe that spending on prevention is 
still underestimated in some countries. Moreover, using different definitions of prevention – for example, 
by including some elements which are by convention part of other health care functions in SHA – might 
result in higher estimates of prevention spending (Box 3 provides an example of this for France). 
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Box 2. Some reporting issues and data limitations remain 
To some extent the variation in prevention spending across countries reflect differences in reporting practices as 
well as the ability to identify expenditure on preventive activities in national data sources. Overall, it would be fair to say 
that prevention expenditure tends to be underestimated for the majority of countries – albeit to varying degrees. 
One reason for this is that certain components of health promotion and disease prevention are in some cases 
missing altogether from countries’ health expenditure, mainly due to a lack of appropriate data sources. This is mostly 
the case for health promotion activities that don't fall under the responsibility of health ministries, but also for preventive 
activities that are not financed by public payers but through private funds. Moreover, national data sources do not 
always allow a distinction between preventive care and other health care services. For example, routine check-ups or 
preventive activities at the primary health care level are frequently reported under curative rather than preventive care 
expenditure. In some individual cases the inability to separate preventive care from other functions might also lead to 
an overestimation of prevention expenditure. Canada, for example, reports provincial expenditure on community and 
mental health – which includes both a preventive component and other services such as treatment or housing – fully 
under the prevention category in the absence of any further information on the nature of the expenditure. Lastly, even if 
expenditure on preventive activities is correctly reported as such, it is not always allocated to the designated 
prevention subcategory. Although this does not explain the underestimation (or in some cases overestimation) of 
prevention spending as a whole, it affects the allocation between prevention subcategories. 
The following list results from a survey conducted by the OECD Secretariat among its group of national health 
accounts data correspondents in 2016 (see Annex 1 for a template of the survey) and summarises some of the main 
reporting issues for the different service types of preventive care: 
Information, education and counselling programmes: Countries typically only include activities under the 
responsibility of health ministries while information campaigns and programmes outside of health ministries are in most 
cases neither included in health nor in prevention expenditure. For example, Sweden does not include mass media 
campaigns carried out by the government-owned stores selling alcoholic beverages, Austria excludes spending on 
school information programmes under the responsibility of the Ministry of Education and Estonia does not consider the 
provision of health and safety information to firms and workers by the Labour Inspectorate. Moreover, personal 
counselling at the primary health care level (e.g. to inform people about the risks of alcohol and tobacco consumption) 
is generally included under curative rather than preventive care expenditure. 
Immunisation programmes: The reporting of organised vaccination programmes is generally in line with SHA 
definitions. However, some countries include expenditure associated with vaccination programmes under curative 
rather than preventive care expenditure. This is true, for example, for the Slovak Republic and to some extent for 
France which includes only the part of organised vaccination programmes financed by local authorities and the 
National Fund for Prevention, Education and Health Information (FNPEIS) under prevention expenditure. Norway and 
Switzerland, on the other hand, include vaccination programmes under prevention expenditure but report them under 
different prevention subcategories. Furthermore, patient-requested vaccinations outside of organised programmes 
(e.g. travel vaccinations) are for most countries included under curative rather than preventive care expenditure. 
Early disease detection programmes: About one-quarter of countries include laboratory and imaging services 
as part of screening programmes in their health expenditure but report them as ancillary services rather than under 
prevention expenditure. This is, for example, the case for Greece, Norway, the Slovak Republic and Sweden. In 
Finland, screening programmes carried out by ambulatory health care centres are included under curative care. 
Switzerland includes early disease detection programmes under prevention expenditure but reports them under a 
different prevention subcategory. 
Healthy condition monitoring programmes: Depending on the type of check-up, between one-third (routine 
general health check-ups) and half (routine dental check-ups, routine antenatal check-ups) of OECD countries include 
associated expenditure under curative care rather than prevention. 
Epidemiological surveillance and risk and disease control programmes: For activities around the design, 
monitoring and evaluation of prevention programmes, countries find it difficult to separate prevention activities from 
governance and health system administration. This means that some prevention expenditure might be reported under 
administration expenditure and vice versa. 
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Box 3. Prevention expenditure in France using different definitions of prevention 
According to SHA data, France spent around 4.6 billion EUR (or 1.9% of all health expenditure) on preventive 
care in 2015. This includes a wide range of individual and collective services aimed at primary and secondary 
prevention, as illustrated in the following table: 
 
For national reporting purposes, however, France includes additional spending items – that is, for certain 
environmental interventions (e.g. pollution abatement, environmental protection, vector control) – that are not included 
in the prevention expenditure figure reported in the SHA framework. Prevention expenditure in 2015 according to this 
broader national definition was about 5.8 billion EUR – one-quarter above the figure reported in SHA. 
In France, both prevention expenditure reported in the SHA framework and according to the national definition 
refer to “institutionalised” prevention; that is, they are limited to preventive activities that are financed or organised by 
national or departmental prevention funds or programmes. This means, for example, that expenditure on immunisation 
programmes is limited to “organised” vaccination financed by local authorities and the National Fund for Prevention, 
Education and Health Information (FNPEIS) – amounting to 134 million EUR in 2015. However, according to the 
French National Agency for Medicines and Health Products Safety (ANSM), total expenditure on vaccination in 2015 
amounted to 547 million EUR. The difference to the 134 million EUR is financed by the French Social Health Insurance 
and private households and is included under the curative care and medical goods categories in the French SHA data. 
Similarly, expenditure on screening and health check-ups is limited to certain “institutionalised” programmes and does 
not include many of the “day-to-day” preventive activities financed by the Social Health Insurance and private 
households.  
According to a DREES (2016) study, such “non-institutionalised” preventive activities and medical goods and 
laboratory services with a preventive purpose, which are normally included under the curative care, ancillary services 
and medical goods categories in the French SHA figures, amounted to about 9.3 billion EUR in 2014. The vast majority 
of this stems from preventive pharmaceuticals (about 4.2 billion EUR) and preventive consultations such as routine 
examinations in practices of GPs, gynaecologists and paediatricians (2.3 billion EUR).  
Source: DREES (2017; 2016); OECD Health Statistics 2017. 
 
  
SHA category EUR, Millions Examples of included activities
Information, education and 
counselling programmes
1 024
Health information and education (e.g. information campaigns for vaccinations 
or against drug abuse and STIs); Advice for maternal and child health
Immunisation programmes 134 Vaccinations
Early disease detection programmes 385 Early detection of cancer and infectious diseases
Healthy condition monitoring 
programmes
2 517
Health check-ups; Occupational health; Maternal and child health in dedicated 
centres; School health services
Epidemiological surveillance and risk 
and disease control programmes
511 Public health monitoring and surveillance; Prevention of occupational hazards
Preparing for disaster and risk and 
disease control programmes
25
Managing of resources for health emergencies and crises through the Health 
Emergency Preparedness and Response Agency (EPRUS)
Total 4 596
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A large part of prevention expenditure is allocated to healthy condition monitoring programmes 
22. Disaggregating prevention expenditure by service type gives a broad overview of the relative 
priorities that countries attach to different preventive activities (Figure 5). In 2015, for the OECD countries 
able to disaggregate spending, around 60% of all prevention spending was allocated to individual 
prevention services including immunisation, early disease detection and healthy condition monitoring 
programmes and 40% to collective prevention services including epidemiological surveillance as well as 
information, education and counselling programmes – although the latter also includes some components 
of individual consumption such as personal advice from GPs to address behavioural risk factors. 
23. Within individual preventive services, a high proportion of spending went on healthy condition 
monitoring programmes. Such programmes were the main prevention spending category for most OECD 
countries and accounted for nearly half (44%) of all prevention expenditure on average. Among the other 
individual services, immunisation programmes and early disease detection programmes each accounted on 
average less than 10% of prevention spending. However, the spending shares attributed to immunisation 
differed vastly between countries and made up nearly one-third of prevention spending in Iceland and 
Latvia but less than 5% in a group of countries including Belgium, Finland, France and Poland. Similarly, 
the early disease detection category was not reported by a number of countries but accounted for up to one-
quarter of prevention spending in Iceland. These disparities can at least partially be explained by a number 
of the aforementioned reporting issues and data limitations. 
Figure 5. Prevention expenditure by service type, 2015 
 
Source: OECD Health Statistics 2017. 
24. The variations in prevention spending figures across OECD countries can also be explained by 
differences in health spending priorities, the scope of coverage of prevention programmes and relative 
prices of these programmes. However, in many instances, such as for public health information campaigns, 
the diversity of these programmes in countries is difficult to quantify making a like-for-like comparison 
nearly impossible. Yet, for other preventive activities, in particular in the areas of immunisation, early 
disease detection and healthy condition monitoring programmes, OECD countries show more similarities 
allowing for more in-depth comparisons. 
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25. Immunisation programmes account for less than 10% of all prevention spending on average 
across the OECD. All OECD countries provide publicly financed vaccination against a variety of 
communicable diseases but spending can differ widely – in 2015, from more than USD 20 per capita in 
Iceland, Germany and Sweden to less than USD 5 in Mexico, Estonia, Poland and Greece (Figure 6). 
Figure 6. Public expenditure on immunisation per capita, selected countries, 2015 
 
Note: "Public" refers to government/compulsory insurance schemes and therefore includes compulsory private insurance. 
Source: OECD Health Statistics 2017. 
26. Whereas all OECD countries have established childhood vaccination programmes with generally 
high coverage rates (Figure 7), some gaps remain leaving unvaccinated populations vulnerable to 
infectious diseases. On average, 96% of children aged one received the recommended vaccination against 
diphtheria, tetanus and pertussis (DTP) and 95% received measles vaccinations in 2015. However, 
coverage rates are below 90% in Mexico for DTP as well as in Italy for measles. Among the 24 OECD 
countries that have followed the WHO recommendation to incorporate the hepatitis B vaccine into their 
national childhood vaccination programmes, coverage was 94% on average in 2015. However, a number of 
countries including Denmark, Finland, Hungary, Iceland, Japan, Norway, Slovenia, Sweden, Switzerland 
and the United Kingdom are not included in this figure as hepatitis B vaccination is not part of their 
general infant vaccination programme but is only recommended for specific high-risk groups (ECDC, 
2016b; OECD, 2017b). As a result, hepatitis B vaccination rates are significantly lower in these countries. 
The biggest variation in vaccination rates exists for influenza vaccination for people aged 65 ranging from 
1.6% in Estonia to 82.3% in Mexico. On average across the OECD, less than half (43%) of the elderly 
population was vaccinated against influenza in 2015. 
27. Even though there is a good degree of overlap in the range of infectious diseases included in 
vaccination programmes, schedules and guidelines may differ among countries which in turn can affect the 
total cost for these programmes. Table 2 provides an overview of vaccination against the human 
papillomavirus (HPV) in a number of OECD countries. Differences exist with respect to targeted age 
groups, numbers of recommended vaccination doses and whether boys should also be vaccinated. 
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Figure 7. Coverage rate for selected vaccinations, OECD average, 2015 
 
Note: Bars show OECD average, whiskers show range across OECD countries. 
Source: OECD Health Statistics 2017. 
Table 2. Recommended immunisations for HPV infection in selected countries 
 
1. Females and males. Two doses with at least 6 months interval. 9-valent vaccine recommended. 
2. Vaccination recommended for older age groups in a 3-dose scheme. 
3. Females only. Recommended only. 
4. Recommendation only for men and women not vaccinated in childhood: 3 doses between 18 and 26 years of life. 
5. Both marketed HPV vaccines (Gardasil and Cervarix) can be given in a 2-dose schedule with a 6 months interval between doses at 
the age of 11-13 years (Gardasil) or 11-14 years (Cervarix). 
6. Three doses in a 0, 1 or 2, 6 month schedule (girls aged 15 to 19 years). 
7. Two doses at 6 months interval. Females only. If the interval between two doses is < 6 months, a third dose may be recommended. 
8. Three dose schedule according to the product information leaflet. Females only. 
9. Females only. First dose can be given at any time during school year 8, to girls who are usually 12 to 13 years old. Second dose to 
be given around 12 months after the first. In September 2014, Scotland moved from a 3-dose to a 2-dose immunisation regimen for 
girls, with the minimum age being 11. In most instances, the second dose is to be administered 1-year post initial dose. For those girls 
who would be aged 15 throughout their immunisation regimen, the 3-dose regimen is to be used. 
Source: ECDC (2016b). 
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28. Finally, in addition to the vaccination plan and the size of the targeted population, the cost of 
vaccines can play an important role in explaining differences in overall vaccination expenditure across 
countries. As with other pharmaceuticals, comparing the prices of vaccines is complicated by a number of 
factors, such as the existence of unpublished rebates on list prices. Nevertheless, Table 3 displays the 
difference in the price of the identical HPV vaccine directly after its accreditation in 2006/2007 in a 
number of OECD countries. The fact that the price in Germany was 80% higher than in the country with 
the lowest price, New Zealand, may serve as an indication as to why spending on immunisation in 
Germany is above that seen in many other countries. 
Table 3. Price of HPV vaccines after accreditation in selected countries 
 
Source: adapted from Haas et al. (2011) 
29. Early disease detection programmes including, for instance, breast cancer screening, account for 
around 7% of total prevention spending on average. While differing in scope and design, some early 
disease detection programmes are part of the benefit package in all OECD countries; however spending 
implications can be very different across countries (Figure 8). 
Figure 8. Public expenditure on early disease detection per capita, selected countries, 2015 
 
Note: "Public" refers to government/compulsory insurance schemes and therefore includes compulsory private insurance. 
Source: OECD Health Statistics 2017. 
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30. In 2003, the Council of the European Union recommended screening programmes for breast, 
cervical and colorectal cancer after reviewing the scientific evidence about their effectiveness. The WHO 
European Region endorsed this recommendation in 2011 (McKee and Rechel, 2014). As a result, screening 
programmes for breast, cervical and colorectal cancer are among the most prominent early disease 
detection programmes across OECD countries. However, depending on the country, these can refer to 
“opportunistic” screening programmes, where the initiative for screening may come from the individual 
health providers or patients themselves, or organised “population-based” screening programmes, in which 
patients are actively identified and encouraged to participate. Evidence suggests that population-based 
screening programmes are more effective and reach patients with low socio-economic status better than 
screening that is conducted in an opportunistic fashion (OECD, 2013). Indeed, countries with non-
population-based breast cancer screening (e.g. Chile, the Czech Republic or the Slovak Republic) are seen 
to have lower screening rates than countries with population-based screening programmes (Figure 9). 
31. It is important to note that in some cases the coverage may only reflect national programmes. For 
example, the figure for Australia refers only to its population-based breast cancer screening programme, 
which is free to all women aged 40 years and over. However, some women aged 50-69 years may choose 
to screen through private providers. Even where nationwide rollout of population-based screening has been 
achieved, differences between countries exist in terms of target populations and other design elements 
which in turn affect overall screening costs. Annex 2 provides an overview of target age, recommended 
frequency and financial access for breast cancer screening programmes across the OECD. 
32. While nearly all OECD countries include screening for breast cancer in their public benefit 
basket (co-payments may apply), screening programmes have been rolled out less comprehensively for 
cervical and colon cancer. Going beyond programmes to screen for breast, cervical and colorectal cancer, 
some countries also have detection programmes for other types of cancer included in the benefit basket. 
Germany, for example, includes bi-annual screening for skin cancer for people above 35 years of age. 
Figure 9. Breast cancer screening in women aged 50-69, 2015 (or nearest year) 
 
1. Programme data. 2. Survey data. 3. Three-year average. 
Source: OECD Health Statistics 2017. 
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33. Apart from cancer screening, early disease detection programmes can also focus on other 
conditions such as infectious diseases or on the detection of foetal anomalies. In some countries, such as 
France, these other programmes may have even higher spending implications compared to cancer 
screening (Figure 10). Some of the cross-country differences in spending on early disease detection 
programmes are explained by differences in the extent to which such screening programmes are in place. 
Figure 10. Spending on early detection of cancer and other diseases in France, 2016 
 
Source: DREES (2017). 
34. It is challenging to clearly distinguish healthy condition monitoring programmes from early 
disease detection; both aim at detecting disease before symptoms appear, so that interventions can be put in 
place when its detrimental effects are still limited. There is, however, still some value in separating the 
two. While early disease detection programmes focus on specific conditions, healthy condition monitoring 
programmes are typically broader in nature. They refer, for example, to the various recommended 
examinations for new-borns, infants and young children to guarantee their physical and psychological 
development in good health. General health check-ups targeting the adult population aim to detect risky 
health behaviours and try to assess whether people are at risk of developing chronic conditions, such as 
cardiovascular diseases or diabetes. Activities carried out as part of these health check-ups can involve the 
establishment of the medical history of the patient, clinical examination, laboratory tests of blood (e.g. for 
cholesterol and glucose levels) and urine (e.g. for protein, erythrocytes, leukocytes, nitrite) and subsequent 
counselling based on examination and test results. Regular check-ups also exist to screen for dental and eye 
diseases. Surveillance of employee health is a particular element of healthy condition monitoring and 
largely depends on the industry and job characteristics. Employees exposed to certain occupational hazards 
may be required to take more frequent and more thorough medical examinations. Figure 11 gives an 
example of the costs of several healthy condition monitoring programmes in Germany. 
35. Across the OECD, healthy condition monitoring programmes account for nearly half of all 
prevention spending. As with the other components discussed in this section, the total spending on healthy 
condition monitoring programmes is affected by (i) the scope of such programmes existing in countries, 
including the legal obligations put on companies to carry out medical examinations; (ii) the size of the 
targeted population; (iii) the price of the individual examinations. Unfortunately, very little is currently 
known about cross-country differences in these components. 
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Figure 11. Spending on selected healthy condition monitoring programmes in Germany, 2009-15 
 
Source: Bundesministerium für Gesundheit (2016). 
36. Generally speaking, specifics in the design of healthy condition monitoring programmes will 
affect their total costs and can explain some of the observed spending differences. In England, the “NHS 
Health Check” was introduced in 2009 targeting adults between 40 and 74 who are invited every 5 years to 
be screened for the risk of developing a chronic condition such as heart disease, stroke, kidney disease, 
type 2 diabetes or dementia
3
 (NHS, 2017). The check-up is frequently undertaken by a nurse or health care 
assistant and involves questions about lifestyle and medical history, the measurement of weight and height, 
blood pressure and a blood test. Based on this, personal advice on how to lower the risk of developing any 
of the most common chronic diseases follows. In total, around 3 million people are invited annually with 
an uptake of around 50%. Annual costs are estimated at around 165 million GBP for this programme 
(Robson et al., 2016). In France, the “bilan de santé” is offered every 5 years to the entire population above 
the age of 16. This check-up appears to be more comprehensive than the NHS check-up but is less 
standardised. It also includes urine tests and can potentially include a dental examination and test of the 
eyes, ears, breath and an electrocardiogram or other complementary tests. It takes place in dedicated test 
centres and not in GP practices (L’Assurance Maladie, 2017). This is again different from the bi-annual 
check-ups for people over 35 in Germany where GPs receive a fee per check-up carried out. In Canada, the 
establishment of check-ups covered under the public benefit package is at the discretion of the provinces. 
Where they exist, for example in Ontario, GPs receive a fee for each check-up carried out but fees vary 
with the patient’s age. 
37. Apart from differences in the design of healthy condition monitoring programmes, spending 
variations are partly influenced by the extent to which countries are able to identify relevant activities. 
Despite these data comparability issues, the relatively strong focus on healthy condition monitoring 
programmes – accounting for nearly half of all prevention spending on average – is striking. While many 
public health interventions have shown to be cost-effective, including a broad range of vaccinations and 
some screening activities, other interventions such as general health or dental check check-ups – both 
                                                     
3 . This is assessed only for patients above 65 years old. 
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interventions that are included under healthy condition monitoring – tend to be less evidence-based or there 
is less of a consensus on frequency of routine check-ups (Chang et al., 2016; Krogsbøll et al., 2012; Riley 
et al., 2013; Davenport et al., 2003). Nevertheless, countries tend to devote a much larger share of their 
prevention spending to healthy condition monitoring compared to immunisation and early disease 
detection, while at the same time room for improvement remains across OECD countries in terms of 
achieving and retaining high vaccination and screening coverage. This suggests that there might be the 
potential to improve the resource allocation within the area of health promotion and disease prevention. 
Government and compulsory insurance are the main financers of preventive care 
38. The vast majority of prevention expenditure is financed through government schemes (i.e. 
central, regional and local government) or compulsory health insurance (i.e. social health insurance and 
compulsory private insurance). In 2015, government and compulsory insurance covered on average 80% of 
prevention expenditure (Figure 12). This share is higher than for overall health expenditure (73% for the 
OECD in 2015). This indicates higher public coverage of preventive care services compared to other health 
care services which tend to be financed to a larger degree through out-of-pocket payments, voluntary 
health insurance and other private funds such as those of non-profit institutions serving households 
(NPISHs) and enterprises. Moreover, Figure 13 shows that government is an important financer across the 
various preventive activities. Even in countries characterised by health insurance systems, where 
compulsory insurance cover significant portions of prevention spending, some vital public health activities 
are financed and organised by central, regional or local government. In some cases, reported spending may 
be restricted to the latter; the United States only submits spending by public health programmes such as 
Maternal and Child Health and School Health and does not include programmes covered under compulsory 
health insurance plans. 
39. Notwithstanding some underreporting of private funding for prevention, a stronger role for public 
payers is to be expected since promoting healthy lifestyles, preventing the spread of non-communicable 
and communicable diseases and surveillance of population health are normally considered as the 
responsibility of governments (Box 4 describes the funding of public health functions in England). From 
an economic perspective, the stronger role of government in health promotion and disease prevention 
might be warranted due to different market failures and behavioural pressures that may lead to unhealthy 
behaviours. Equity considerations can also justify government intervention as prevention policies provide 
an opportunity to address health inequalities as they can be targeted at at-risk individuals and population 
groups (McDaid et al., 2015b). To a lesser extent the higher share of public financing of preventive care 
might also reflect the greater availability of routinely collected administrative data for government schemes 
and compulsory health insurance compared to private funding sources. 
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Figure 12. Prevention expenditure by type of financing, 2015 
 
Source: OECD Health Statistics 2017. 
Box 4. Funding of public health functions at the local level in England 
Under the 2012 Health and Social Care Act much of the responsibility for public health at the local level was 
transferred from the NHS to local government via ring-fenced allocations; such grants account for roughly three-
quarters of overall government spending on public health and prevention activities in England. According to the 
conditions, the grants allocated to each local authority must be used for the purposes of carrying out a raft of public 
health functions (as specified in the National Health Service Act 2006) and can be used in conjunction with other 
sources of funding. The allocation is the responsibility of the local authority but should be in line with the overall 
priorities set. Reporting on the spending is made on a quarterly basis and is reviewed by Public Health England (PHE) 
on behalf of the Secretary of State for Health. The lines of expenditure that need to be reported are as follows: 
 
Source: Department of Health (2016). 
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40. Among private expenditure on preventive care, employer-based enterprise schemes tend to be the 
main financing arrangements. Enterprise schemes primarily include the direct provision and financing of 
occupational health services by private corporations to their employees. For five countries (Portugal, 
Slovenia, Ireland, Estonia and France), enterprises accounted for one-third or more of prevention 
expenditure in 2015 (see Box 5 for an example of employers’ obligations on health check-ups). 
Occupational health care is included under healthy condition monitoring programmes and can take up a 
significant share of this function (Figure 13). About one third of OECD countries do not report any 
prevention expenditure attributable to enterprises. This likely reflects difficulties in estimating such 
expenditure due to a lack of appropriate data sources, rather than the non-existence of preventive activities 
carried out and paid for by private corporations. 
41. Similarly, prevention expenditure paid for by NPISHs through their own funds is not reported by 
nearly half of countries, most likely also due to a lack of data sources. However, the non-reporting of this 
spending element is unlikely to influence aggregate spending much as NPISHs account for 5% or less of 
prevention expenditure where reported (except in Luxembourg, Finland and Hungary). Examples of 
NPISHs financing include public awareness campaigns or information exchanges (e.g. alcoholism, 
substance abuse, safe sex) typically financed through donations (from the general public, governments or 
corporations) and provided by self-help organisations, charities, etc. 
42. Lastly, out-of-pocket payments, either as direct payments or in the form of cost-sharing for 
vaccinations, screening or routine check-ups (e.g. dental check-ups), account for a relatively small share of 
prevention expenditure overall. Nevertheless, a handful of countries – including Switzerland, Austria, 
Korea and the United Kingdom – reported a more significant contribution out of households’ own 
resources. The implications of this are unclear. On the one hand, co-payments can limit access to vital 
personal preventive services, in particular for the vulnerable population who could benefit most from these 
services. A different story may be self-payment for preventive services in cases where patients are not 
included in the target population of a prevention programme. Here, the question again arises as to whether 
these services are effective in the first place. 
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Box 5. Medical examinations in the workplace: recent changes in France 
The recent Loi El Khomri reformed France's Labour Code and included changes regarding employers' obligations 
on health check-ups. In summary, the new law abolished the principle of systematic medical examinations for all 
employees in France.  
As of 1 January 2017, newly hired employees are no longer required to pass a medical examination before 
starting work (except for minors and night-shift workers). This is replaced by a simple information and prevention visit 
(VIP) once hired. The VIP is an interview carried out by a doctor, a medical intern or a nurse within 3 months of starting 
work in which the employee is asked about their state of health and informed about the risks associated with their 
activity as well as any prevention measures to be implemented.  
Also, the period between each examination is now dependent on the working conditions specific to the 
employee's employment. Previously, an employee had to undergo a periodic medical examination every two years. 
Now they must have a follow up within a maximum of 5 years after the first visit. However, this is reduced to 3 years for 
workers with disabilities, night-shift workers and persons in receipt of a disability pension. 
Other high-risk employees benefit from so-called "enhanced individual follow-up". These include those exposed 
to certain hazards such as lead or asbestos, carcinogens, as well as higher risk occupations e.g. assembly of 
scaffolding, etc. Such employees are seen by an occupational physician before hiring and undergo a more advanced 
examination to ensure that the employee's state of health does not constitute a danger for colleagues. The visit must 
be renewed within a time limit set by the occupational physician and in any case not less than 4 years. An intermediate 
visit must in the meantime be carried out by a health professional (such as a nurse, for example) within 2 years after 
the first visit. 
The Labour Code (article R4624-21) also requires the employer to organise a medical check-up within 8 days for 
an employee who returns to the company after an absence following maternity leave, absence due to occupational 
disease or an absence of at least 30 days following a non-occupational illness, an accident or an accident at work. 
Failure to comply with its obligations can leave the employer liable to sanctions in the form of a fine (Article 
R4745-1 of the Labor Code) or even imprisonment for repeated offences (L4745-1). An employee can also take legal 
action against his employer in the event of damage suffered as a result of the employer's failure to meet their medical 
examination obligations.  
Changes in the regulations are likely to result in a reduction of the costs of occupational health care for 
employers in France. 
Source: Ministère du Travail, de l’Emploi, de la Formation professionnelle et du Dialogue social (2017) 
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Figure 13. Prevention expenditure by type of service and financing, selected countries, 2015 
 
Source: OECD Health Statistics 2017. 
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3. RECENT TRENDS IN PREVENTION EXPENDITURE 
Prevention expenditure was affected post economic crisis more than other health care services 
43. While over the longer term, spending on prevention as a share of overall spending has been 
relatively stable, one recent short-term observation is that prevention expenditure was affected more by the 
economic crisis than other health care services (Figure 14). The slowdown in overall health spending in the 
aftermath of the economic and financial crisis affected all spending categories, but to varying degrees. The 
reduction in growth rates was particularly pronounced for pharmaceutical spending (OECD, 2016) and 
prevention spending whereas frontline services, including inpatient and outpatient care, were much less 
affected.  
Figure 14. Growth of health expenditure per capita for selected functions, OECD average, 2005-15 
 
Source: OECD Health Statistics 2017. 
44. Despite initially protecting public health budgets, prevention spending contracted in more than 
half of OECD countries both in 2009-2011 and in 2011-2013 (Table 4). This may appear counter-intuitive 
in that in times of economic uncertainty, governments might wish to prioritise more cost-effective 
prevention measures for long-term savings. However, short-term fiscal concerns can prevail. Notable 
decreases between 2009 and 2013 could be observed in the southern European countries that were 
especially hard hit by the economic crisis including Greece, Portugal and Spain, but also in Hungary, Israel 
and Poland. Belgium and France saw substantial declines in 2009-2011 and the Czech Republic, Estonia 
and Mexico in 2011-2013. Even in countries that did not experience such drastic declines in prevention 
spending, growth rates between 2009 and 2013 were generally reduced compared to earlier periods. In the 
most recent period (2013-2015), prevention spending has seen renewed growth in many countries and has 
been roughly in line with overall health spending growth for the OECD as a whole. 
45. Public health budgets have been targeted for cuts during the economic crisis in a number of 
European countries (Mladovsky et al., 2012). In Estonia, the cuts in 2009 focused on non-communicable 
diseases. Preventive spending was also reduced in Italy and Latvia. Moreover, Iceland, Latvia and 
Lithuania planned to merge or close public health bodies in the wake of the crisis. On the other hand, a 
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number of countries have introduced reforms to strengthen public health measures, such as increasing the 
taxes on alcohol and tobacco, introduce taxes on food and beverages (on sugar or fat) to address poor 
nutrition (OECD, 2017a) or other measures to encourage healthy nutrition, exercise and screening 
(Mladovsky et al., 2012). Yet, many of these initiatives mainly related to changes to the legal framework 
and have only small spending implications. 
Table 4. Growth of prevention expenditure per capita by country, 2005-15 
 
Note: Values refer to annual average growth rates (%) in real terms. Darker bars indicate increases; lighter bars indicate decreases. 
1. Not included in the OECD average because data not available for all periods. 
Source: OECD Health Statistics 2017. 
46. Due to data limitations it is difficult to identify clear trends for the respective components of 
preventive spending. As healthy condition monitoring is generally the biggest component of total 
preventive spending, it is not surprising that the development of this spending component is an important 
2005-07 2007-09 2009-11 2011-13 2013-15
Australia 16.6 -3.3 7.8 -0.8 3.6
Austria 3.0 -2.7 1.6 3.3 2.9
Belgium 3.7 15.9 -10.3 1.2 0.1
Canada 2.3 3.0 -1.2 2.4 3.2
Czech Republic 17.4 6.9 1.3 -10.4 -4.2
Denmark 1.7 5.5 1.6 3.7 0.8
Estonia 19.4 10.5 2.3 -10.5 9.4
Finland 5.8 -3.0 0.1 2.3 8.7
France 3.1 7.1 -7.9 0.5 -2.6
Germany 6.9 3.3 -3.0 0.1 1.8
Greece¹ .. .. -11.3 -10.6 8.6
Hungary -5.8 -6.2 -3.8 -10.2 0.8
Iceland 4.3 -7.3 -3.9 4.0 -1.9
Ireland¹ .. .. .. .. -1.1
Israel¹ -4.5 3.3 -12.9 -10.1 ..
Italy 3.1 2.0 -1.3 -1.7 0.1
Japan 2.4 16.7 3.1 0.7 12.5
Korea 17.6 22.9 3.2 8.7 11.1
Mexico 4.4 13.3 16.7 -5.4 1.2
Netherlands 0.9 4.4 -1.1 -2.9 -1.3
Norway 3.5 11.5 4.9 5.1 3.2
Poland 7.0 8.0 -2.9 -4.7 5.4
Portugal -4.5 2.6 -1.4 -13.0 0.4
Slovenia 4.5 1.5 4.0 -2.5 -11.3
Spain 5.2 8.5 -11.4 -5.7 1.3
Sweden 2.9 7.0 0.9 5.3 1.8
Switzerland 3.3 6.4 -1.9 1.4 1.5
United Kingdom¹ .. .. .. .. 4.4
United States 3.3 3.5 -2.4 -0.1 -0.3
OECD25 5.3 5.5 -0.2 -1.2 1.9
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contributing factor to the general trends. This is, for example, true in Korea and Sweden where growth for 
this component explains a large part of total prevention spending growth since 2009. In Sweden, increased 
spending for information, education and counselling programmes has also contributed to prevention 
spending growth in recent years. In Iceland too spending for information, education and counselling 
programmes increased strongly since 2011, compensating for slower increases or reductions in other 
prevention measures. Yet, in Greece, much of the total reduction since 2009 can be attributed to cuts in 
spending for information, education and counselling. 
Some of the slowdown since 2009 is due to volatility in immunisation spending 
47. One component of prevention expenditure that has shown some volatility in the past is spending 
on vaccination programmes. There are different reasons for this: pandemic emergencies can require 
extraordinary vaccination plans, scientific advances that make new vaccines possible can lead to updates in 
national vaccination plans and attitudes of the population towards voluntary vaccinations may change. One 
example of emergencies was the H1N1 swine flu pandemic in 2009/2010. After the WHO raised the 
pandemic alert to the highest possible level in June 2009, countries took the required measures to protect 
their populations to the greatest extent possible. Effective vaccines against the H1N1 virus became 
available as of fall 2009 leading to significant one-off expenditure for vaccinations which in turn resulted 
in a peak of prevention expenditure in many countries around 2009 (Figure 15). This peak explains to 
some extent the reduction of prevention spending growth since 2009. 
48. However, the actual spending for vaccinations was smaller than anticipated in many countries 
and far less than the acquisition costs.
4
 In Germany, for example, the authorities initially ordered 50 
million doses of vaccines – eventually covering 25 million people as two doses per persons were deemed 
necessary to be effective – but in the end, only around 5 million vaccinations against H1N1 were carried 
out at a cost of roughly 70 million EUR. This led to a 1% increase in preventive spending in 2009. For 
Germany, a bigger factor in explaining the increase in vaccination spending around that time was the 
introduction of the “Act to strengthen competition in Statutory Health Insurance” which came into effect in 
April 2007 and made a number of vaccinations mandatory for all Statutory Health Insurance Funds 
(Mueller and Boehm, 2009). Before that time, vaccinations were at the discretion of the individual funds. 
                                                     
4 . Current health expenditure as defined in the SHA refers to the final consumption of health care services 
and goods. The acquisition of unused vaccines is not considered as final consumption and should hence not 
be part of prevention spending. However, for some countries prevention expenditure includes the 
acquisition of unused vaccines rather than just the consumption of the vaccine. 
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Figure 15. Evolution of prevention expenditure per capita, real terms, selected countries, 2006-15 
 
Source: OECD Health Statistics 2017. 
49. Changes in national vaccination plans also appeared to have had an important impact on 
preventive costs: the inclusion of the vaccination against HPV infection – preventing genital warts and 
lesions that can cause different forms of cancer such as cervical cancer – in public prevention programmes 
increased vaccination costs substantially, in Germany and elsewhere. Public coverage for HPV 
vaccinations has been gradually introduced since 2006, the first year that vaccines became available. Part 
of the significant impact of HPV on total immunisation spending is related to the fact that – compared to 
other diseases – the costs of the HPV vaccine is relatively high5 (WHO, 2013). Figure 16 shows the trend 
in spending for some selected vaccinations over the last 10 years in Germany, also reflecting changes in 
the national vaccination plan. The rise in costs for influenza vaccination in 2009 is closely related to the 
H1N1 swine flu pandemic. The spending peak in 2008 for HPV vaccination is due to the increased number 
of vaccinations carried out in the first year after inclusion in the benefit basket. The change in the 
vaccination guidelines – from a recommended three doses within one year for girls between 12 and 17 in 
2007 to two doses within 6 months for girls between 9 and 14 in 2014 – does, thus far, not seem to have 
affected the total costs of HPV vaccinations. The uptake of the cost of vaccination against the rotavirus in 
2014 is most likely due to its inclusion in the vaccination recommendations by the permanent vaccination 
committee in August 2013. 
                                                     
5. The cost of H1N1 vaccination was 14 EUR per dose in Germany in 2009 (9 EUR vaccine plus 5 EUR 
vaccination service charge) (Rieser and Siegmund-Schultze, 2009). Cost for one dose HPV vaccine is 
around 160 EUR (Deutsches Krebsforschungszentrum, 2016). 
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Figure 16. Spending on selected vaccinations in Germany, 2006-15 
 
Source: ABDA (2016). 
The introduction of population-based screening has driven up spending 
50. Many OECD countries have introduced population-based cancer screening programmes in recent 
decades and achieved nationwide rollout
6
 by the end of the 2000s – in particular for breast and cervical 
cancer screening. While some countries completed the nationwide rollout of population-based breast 
cancer screening programmes already in the 1990s (e.g. Australia, Luxembourg, the Netherlands, Sweden) 
or even earlier (e.g. Finland, Iceland), most other OECD countries followed during the 2000s. Similarly, 
for cervical cancer screening, several OECD countries have rolled out nationwide population-based 
programmes since the 2000s, even though, compared with breast cancer screening, cervical cancer 
screening tends to be less often population-based. In addition to breast and cervical cancer screening, 
colorectal cancer screening has become more widely available across OECD countries in recent years, 
including a number of countries where the nationwide rollout of population-based screening programmes 
has been completed (OECD, 2013). 
51. France introduced nationwide population-based breast cancer screening in 2004 under the First 
(2003-2007) and Second (2009-2013) French Cancer Plans (Moutel et al., 2014) and achieved a significant 
increase in population coverage from 38% of women aged 50-69 screened in 2004 to 53% in 2009 
(Figure 17). At the same time, spending on cancer screening in France doubled (in nominal terms). In 
2003, 91 million EUR were spent on the early detection of cancer, increasing to 182 million EUR by 2009. 
However, between 2009 and 2016, breast cancer screening rates have remained fairly constant suggesting 
that further increasing or maintaining screening coverage is difficult once the nationwide rollout of a 
                                                     
6. “Nationwide rollout is considered completed if at least ca. 90% of the eligible target population in the 
respective region or country should have received at least one personal invitation to attend the screening 
programme, and all elements of the screening services should be fully functional in order to assure that 
every eligible person has an equal opportunity to participate in screening.” (OECD, 2013; p. 67) 
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population-based screening programme has been achieved. Additional measures might be necessary to 
reach the rest of the population (OECD, 2013). Spending on early cancer detection has also remained fairly 
stable from 2009 to 2016 but has declined somewhat in recent years after reaching a peak of 194 million 
EUR in 2013. 
Figure 17. Breast cancer screening and early cancer detection spending in France, 2004-16 
 
Note: Screening rates are based on programme data and refer to women aged 50-69. 
Source: OECD Health Statistics 2017; DREES (2017; 2016; 2013). 
52. Korea launched the National Cancer Screening Programme (NCSP) in 1999 covering free-of-
charge breast, cervical and stomach cancer screening for Medical Aid
7
 beneficiaries (Kim et al., 2011). In 
subsequent years, the target population as well as the scope of the NCSP has been expanded. For example, 
in 2002, the target population was expanded to include National Health Insurance (NHI) beneficiaries in 
the lower 20% income bracket; in 2003, liver cancer was added to the NCSP and the target population 
expanded to the lower 30% of NHI beneficiaries; in 2004, colorectal cancer screening was added to the 
NCSP; in 2005, the target population was expanded to the lower 50% of NHI beneficiaries (Kim et al., 
2011). Cost-sharing applies to the upper 50% of NHI beneficiaries who are not covered by the NCSP free-
of-charge. However, whereas these patients initially had to cover 50% of the screening expenses out of 
their own pockets, cost-sharing was reduced to 20% in 2005. In 2010, cost-sharing requirements were 
removed for cervical cancer screening and reduced to 10% for breast, colorectal, stomach and liver cancer 
screening (Kim et al., 2011). 
53. All these changes have contributed to the dramatic increases in screening rates as well as the 
substantial growth of spending on early disease detection observed in Korea since the early 2000s 
(Figure 18). Breast cancer screening coverage continuously increased from only 14% in 2003 to 67% in 
2015. Similarly, population coverage for cervical cancer screening saw a four-fold increase within a 
decade, from 14% in 2003 to 58% in 2015. These large expansions in coverage were accompanied by 
substantial spending increases. In 2015, expenditure on early disease detection amounted to WON 689 
billion, a more than 500% increase (in nominal terms) from the WON 108 billion spent in 2003. The 
increases were especially large between 2004 and 2005, when the amount spent on early disease detection 
                                                     
7. The Korean Medical Aid programme provides medical services for the low-income population. 
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more than doubled. This coincided with the expansion of the NCSP’s target population and the relaxing of 
cost-sharing requirements. 
Figure 18. Cancer screening rates and early disease detection spending in Korea, 2003-15 
 
Note: Screening rates are based on programme data. Prior to 2008, data refer to women aged 50 and over for breast cancer 
screening and to women aged 30 and over for cervical cancer screening. From 2008 onwards, data refer to women aged 50-69 and 
30-69, respectively. 
Source: OECD Health Statistics 2017. 
54. Less is known about the development of spending associated with healthy condition monitoring 
programmes. Generally, the biggest impact on overall costs will be associated with the introduction of such 
a programme or changes to the target groups. For example, changes in the scope of healthy condition 
monitoring programmes have been at the heart of the strong increase in prevention spending in Korea in 
recent years. In 2007 the Korean government introduced the “National Screening Program for Transitional 
Ages” – a health check-up programme focussing on two specific age groups, at 40 and 66 (Kim et al., 
2012) – and the “National Health Screening Program for Infants and Children” (Moon, 2010). Moreover, 
since 2012, health check-ups were also extended to beneficiaries of the Medical Aid programme. Similarly, 
the “NHS Health Check” was introduced in 2009 in England and can be expected to have contributed to 
the rise of preventive spending in that year. 
55. On the other hand, after a review questioning the effectiveness of health check-ups, such 
examinations were put on hold in Denmark in 2013 (Krogsbøll et al., 2013). In Ontario, Canada, criticism 
about the usefulness of annual check-ups has also led to a reassessment of the programme (Ministry of 
Health and Long-Term Care Ontario, 2017). As of 2013, the scope of “Periodic Health Visits” has been 
refocused making it more patient-specific and moving away from a standardised one-size fits all 
examination. The fee schedule now reflects differences in age groups and pre-existing conditions. For 
healthy individuals the fee was cut from CAD 72 to CAD 50 with estimated savings in fees totalling CAD 
7.3 million in the 2012/13 financial year and CAD 29 million in the 2013/14 financial year. 
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4. CONCLUSIONS AND WAYS FORWARD 
56. The “Healthy Ireland” strategy, Austria’s public health promotion strategy (as part of the 
agreement between the federal and state governments) or Mexico’s national strategy against obesity, 
overweight and diabetes, show that strengthening prevention and public health is high on the agenda of 
health ministries across the OECD. Given the strong evidence on the cost-effectiveness of many 
interventions in health promotion and disease prevention, the findings from this analysis that average 
spending on prevention and public health interventions accounts for less than 3% of overall health 
expenditure (and has remained more or less stable over time) may appear surprising and at odds with the 
importance attached to public health and prevention by policymakers. It should be stressed though, that not 
all public health measures have spending implications that are reflected in prevention expenditure as 
measured under SHA. 
57. Within overall prevention spending, healthy condition monitoring programmes, which cover 
routine medical and dental check-ups as well as occupational health services, account for almost half of 
prevention spending, whereas spending on immunisation and screening programmes combined typically 
account for less one-fifth of prevention spending. Given the debate around the scope and frequency of such 
check-ups and their effectiveness and potential to save costs, this may raise questions regarding the optimal 
resource allocations given the constraint on health budgets. A further qualitative analysis could highlight 
the variation in prevention and public health priorities across countries but could also help re-assess 
whether countries focus on the right prevention programmes – that is, those that bring the most value for 
money. 
58. Recent spending trends show that prevention spending was cut during the financial crisis. Some 
of this coincided with the increases in vaccination spending to fight the H1N1 epidemic which peaked in 
2009 and dropped thereafter. Over the longer term, spending for vaccination programmes has increased in 
the last decade, not least due to the inclusion of the expensive HPV vaccination in national immunisation 
plans. Cancer screening programmes have also been rolled out in the 2000s and have been a driver of 
spending on early disease detection. Check-ups for healthy adults have been introduced in a number of 
countries but were redesigned in others to reduce costs given some disappointing evaluations of 
population-wide healthy condition monitoring programmes. Generally, it seems that advancement in 
technology and knowledge, such as the development of new vaccines as well as changes in unit costs are 
driving prevention spending trends. Again, gathering more information on other prevention domains, such 
as occupational health care or school prevention programmes, is required to get a more complete picture. 
59. This paper compares and analyses spending on prevention and public health in OECD countries 
at an aggregate level as well as at a more detailed service type level. The analysis is the first to use the 
revised definition of prevention spending and the new structure of subcategories introduced under the 
updated SHA framework. For health spending in general, the revision of the SHA framework has led to 
greater coverage of countries reporting the different health spending elements and improved international 
comparability. This is also true in the area of prevention spending. Nevertheless, limitations in countries’ 
ability to identify and report the elements of prevention and public health spending and all related 
subcategories still exist and affect data comparability. This is an iterative process and more can be done to 
further improve the comparability of these figures, for instance by providing additional guidance to 
national health accounts data correspondents about how to classify particular preventive activities. 
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ANNEX 1: SURVEY ON ACCOUNTING OF PREVENTION EXPENDITURE UNDER SHA 
 
 
1. What data sources are you using for the estimation of expenditure on preventive care (HC.6)? Please select all that apply.
Public accounts/budgets
Financial records of social/public health insurance
Provider-specific data sources
National accounts - supply/use tables
Company accounts
Ad-hoc studies or irregular surveys
Expert opinion/estimate
Other, please specify:
National accounts - government expenditure by function (COFOG)
Surveys of household spending
Activity
Is the activity 
included in your 
health accounts?
Under which HC 
categories is the 
activity classified?
Under which HP 
categories is the 
activity classified?
Under which HF 
categories is the 
activity classified?
Additional information
(e.g. specify the content of the activity, estimation method used, how/why is activity 
allocated to several different HC categories, reason for not including the activity, etc.)
Childhood vaccination programme
Public information campaigns providing information 
on the vaccination programme
Select…
Service provision (cost of vaccine, health care 
personnel, overheads)
Select…
Programme design, monitoring and evaluation Select…
Cancer screening programmes (e.g. breast cancer)
Public information campaigns providing information 
on the screening programme
Select…
Service provision (cost of mammography, health care 
personnel, overheads)
Select…
Programme design, monitoring and evaluation Select…
General medical examination programme
(routine check-ups)
Public information campaigns providing information 
on the medical examination programme
Select…
Service provision (cost of medical examination, 
health care personnel, overheads)
Select…
Programme design, monitoring and evaluation Select…
Other activities
Vaccination requested by the patient outside of an 
organised vaccination programme (e.g. vaccination 
for travel)
Select…
Regular dentist visits for routine check-up (e.g. 
examination of teeth/gums/mouth, x-rays, cleaning, 
advice on oral hygiene)
Select…
Routine antenatal check-ups (maternity outpatients) Select…
Monitoring of drinking water and food in relation to 
water and food-borne disease
Select…
Charity providing information and support to reduce 
incidence of suicide
Select…
Preventive medicines (e.g. antihypertensive drugs, 
statins)
Select…
2. For each of the following activities, please indicate if it is included in your health accounts (i.e. HC.1-HC.7). If the activity is included, please specify under which HC, HP and HF categories.
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Activity
Is the activity 
included in your 
health accounts?
Under which HC 
categories is the 
activity classified?
Under which HP 
categories is the 
activity classified?
Under which HF 
categories is the 
activity classified?
Additional information
(e.g. specify the content of the activity, estimation method used, how/why is activity 
allocated to several different HC categories, reason for not including the activity, etc.)
Mass media campaigns providing health information to the 
public or specific groups about how to reduce risks (e.g. 
campaign against drinking & driving, anti-drug campaign)
Select…
School information programme to prevent substance abuse 
(alcohol, nicotine, drugs)
Select…
Activities at the primary health care level (e.g. counselling 
of patients at risk by physicians and other health care 
professionals)
Select…
Making regulations (e.g. advertising or labelling regulations) Select…
Costs to those regulated of complying with regulations (e.g. 
costs of new labelling)
Select…
Enforcing of regulations (e.g. inspection, monitoring, 
tackling contraventions)
Select…
3. For each of the following activities related to interventions against behavioural risks (e.g. harmful drinking, smoking, substance abuse), please indicate if it is included in your health 
accounts (i.e. HC.1-HC.7). If the activity is included, please specify under which HC, HP and HF categories.
Activity
Is the activity 
included in your 
health accounts?
Under which HC 
categories is the 
activity classified?
Under which HP 
categories is the 
activity classified?
Under which HF 
categories is the 
activity classified?
Additional information
(e.g. specify the content of the activity, estimation method used, how/why is activity 
allocated to several different HC categories, reason for not including the activity, etc.)
Routine medical check-ups required for employees (on or 
off-business premises)
Select…
Providing health and safety information to firms and workers 
about sources of hazards and how to reduce risks (e.g. 
about the safe handling of dangerous materials)
Select…
Making regulations to protect employees’ health and safety 
(e.g. making wearing of hard hats mandatory)
Select…
Costs to those regulated of complying with regulations (e.g. 
buying mandatory equipment)
Select…
Enforcing of regulations (e.g. inspection, monitoring, 
tackling contraventions)
Select…
4. For each of the following activities related to occupational health care and interventions against occupational risks, please indicate if it is included in your health accounts (i.e. HC.1-HC.7). If 
the activity is included, please specify under which HC, HP and HF categories.
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5. Do you include any other main spending items under preventive care (HC.6) that go beyond the 
activities described in Q.2, Q.3 and Q.4? Please specify.
Select…
7. Do you have any other comments you consider relevant for your estimate of preventive care (HC.6)?
8. Are you willing to provide more details regarding your responses?
6. Do you include any activities under preventive care (HC.6) that are outside of an organised prevention 
programme, i.e. activities at the individual's own initiative? Please specify.
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ANNEX 2: BREAST CANCER SCREENING PROGRAMMES IN THE OECD 
 
Note: Changes in breast cancer screening programmes since 2010 are not included in the tables. 
Source: Adapted from OECD (2013). 
  
Wider age range
(20 years+)
Narrower age range
Wider age range
(20 years+)
Narrower age range
Australia (50-69), Belgium 
(50-69), Finland (50-69), 
France (50-74), Germany 
(50-69), Hungary (45-65), 
Iceland (40-69), Israel (50-
74), Italy (50-69), Korea 
(40+), Latvia (50-69), 
Luxembourg (50-69), 
Netherlands (50-75), New  
Zealand (45-69), Norw ay 
(50-69), Poland (50-69), 
Portugal (45-69), Spain (50-
69), Sw eden (40-74), 
United Kingdom (50-70)
Ireland (50-64) Czech Republic (45+), 
Greece (40+), Slovak 
Republic (40-69), 
United States (50+)
Chile (50-54)
Frequent access
(every two years)
Less frequent access
(every three years)
Australia, Belgium, Finland, 
France, Germany, 
Hungary, Iceland, Ireland, 
Israel, Italy, Korea, Latvia, 
Luxembourg, Netherlands, 
New  Zealand, Norw ay, 
Poland, Portugal, Spain, 
United Kingdom
Free access Access with fee Free access Access with fee Free access Access with fee
Australia, Belgium, Finland, 
France, Germany, Ireland, 
Italy, Japan, Korea, Latvia, 
Luxembourg, Netherlands, 
New  Zealand, Norw ay, 
Portugal, Spain, Sw eden, 
United Kingdom
Hungary, Iceland, Israel, 
Poland
Denmark, Sw itzerland, 
Turkey
Canada, Slovenia Chile, Czech Republic, 
Greece, Slovak 
Republic
United States
Wider age range
(20 years+)
Canada (50-69), Denmark (50-69), Japan (40+), 
Slovenia (50-69), Sw itzerland (50-70), Turkey 
(50-69)
Target age in breast cancer screening programmes, 2010
Recommendations on frequencies of breast cancer screening, 2010
Breast cancer screening programmes and financial access, 2010
Nationwide population-based Population-based but not nationwide Non-population-based
Nationwide population-based Population-based but not nationwide Non-population-based
Frequent access
(every two years)
Frequent access
(every two years)
Canada, Denmark, Japan, Slovenia, Sw itzerland, 
Turkey
Chile, Czech Republic, Greece, Slovak Republic, 
United States
Nationwide population-based Population-based but not nationwide Non-population-based
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